Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances

Lisbon May 2014

Summary

This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as PDF

EMCDDA actions on monitoring and responding to new drugs
EMCDDA–Europol Joint Report on MDPV: a summary
Risk Assessment Report of a new psychoactive substance: MDPV
Annex 1: Technical report on MDPV
Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
Participants of the risk assessment meeting